The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Health Catalyst Inc. shares valued at $7,122 were sold by Llewelyn Linda on Sep 15. At $10.99 per share, Llewelyn Linda sold 648 shares. The insider’s holdings dropped to 55,865 shares worth approximately $0.56 million following the completion of this transaction.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Also, Burton Daniel D. purchased 90,750 shares, netting a total of over 996,970 in proceeds. Following the buying of shares at $10.99 each, the insider now holds 703,062 shares.
Before that, Orenstein Daniel H. had sold 2,838 shares from its account. In a trade valued at $31,978, the General Counsel traded Health Catalyst Inc. shares for $11.27 each. Upon closing the transaction, the insider’s holdings decreased to 2,838 shares, worth approximately $1.0 million.
As published in their initiating research note from KeyBanc Capital Markets on September 16, 2022, Health Catalyst Inc. [HCAT] has been a Sector weight. Analysts at Piper Sandler downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid September. As of August 05, 2022, Stifel has decreased its “Buy” rating to a “Hold” for HCAT. Earlier on August 05, 2022, JP Morgan downgraded its rating. Their new recommendation was “a Neutral” for HCAT stock which previously was a “an Overweight”.
Analyzing HCAT’s Price Performance
On Wednesday, Health Catalyst Inc. [NASDAQ: HCAT] plunged -0.99% to $10.04. The stock’s lowest price that day was $9.915, but it reached a high of $10.405 in the same session. During the last five days, there has been a drop of approximately -10.12%. Over the course of the year, Health Catalyst Inc. shares have dropped approximately -74.66%. Shares of the company reached a 52-week high of $40.65 on 01/03/22 and a 52-week low of $9.89 on 09/19/22. A 50-day SMA is recorded $13.29, while a 200-day SMA reached $21.65. Nevertheless, trading volume fell to 1.5 million shares from 0.63 million shares the previous day.
Support And Resistance Levels for Health Catalyst Inc. (HCAT)
According to the 24-hour chart, there is a support level at 9.84, which, if violated, would cause prices to drop to 9.63. In the upper region, resistance lies at 10.32. The next price resistance is at 10.61. RSI (Relative Strength Index) is 32.44 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.80, which suggests the price will decrease in the coming days. Percent R is at 92.50%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Health Catalyst Inc. subject to short interest?
Stocks of Health Catalyst Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 70000.0 shares to 4.03 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 3.96 million shares. A jump of 1.74% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.96 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.96.
Which companies own the most shares of Health Catalyst Inc. (HCAT)?
According to The Vanguard Group, Inc. filings, the company currently owns 5,492,511 shares, which is about 10.04% of the total HCAT shares outstanding. The investor’s shares have appreciated by 276,997 from its previous 13-F filing of 5215514.0 shares. With the completion of the buy transaction, AllianceBernstein LP’s stake is now worth $53,563,296. BlackRock Fund Advisors acquire a 21.06% interest valued at $46.15 million while Millennium Management LLC purchased a 2,213,500 stake. A total of -964,485 shares of Health Catalyst Inc. were bought by Wellington Management Co. LLP during the quarter, and -190,271 were sold by ClearBridge Investments LLC. In its current portfolio, abrdn, Inc. holds 1,410,383 shares valued at $16.92 million.
In spite of this, 16 analysts ranked Health Catalyst Inc. stock as an Overweight at the end of 2022. On April 14, 2022, Guggenheim assigned a price target of “a Buy” to the stock and initiated coverage with a $39.